Physician profile
Christopher G Putney
NPI 1295737245
$19,063.06
in general payments reported to CMS, 2019-2025
70 companies · $2,406 in 2025
The $2,406 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,130 · 2020: $2,618 · 2021: $3,123 · 2022: $2,840 · 2023: $2,745 · 2024: $2,201 · 2025: $2,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,351.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,647.61 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,053.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,555.40 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $1,538.82 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $1,518.17 | 2019-2025 | |
| Amgen INC. | $843.73 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $828.39 | 2019-2025 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $827.97 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $636.39 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $572.72 | 2019-2025 | Unithroid, Crexont |
| Antares Pharma, INC. | $491.65 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $343.04 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $296.61 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $295.77 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Corium, LLC | $294.58 | 2022-2025 | Azstarys |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Putney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.